130 related articles for article (PubMed ID: 28748882)
1. Superiority of peginterferon α-2a and ribavirin combination over peginterferon α-2a monotherapy in the management of hemodialysis patients with chronic Hepatitis C virus infection.
Al-Ghamdi SMG; Alaulaqi N; Al-Amoudi AA; Alghamdi A; Zagnoon A; Sadiq BB
Saudi J Kidney Dis Transpl; 2017; 28(4):799-805. PubMed ID: 28748882
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
Alsaran K; Sabry A; Shaheen N
Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
[TBL] [Abstract][Full Text] [Related]
5. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
7. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.
Howell CD; Jeffers LS; Cassidy W; Reddy KR; Hu S; Lee JS
J Viral Hepat; 2006 Jun; 13(6):371-6. PubMed ID: 16842439
[TBL] [Abstract][Full Text] [Related]
9. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
Urbanek P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Husa P
Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1004-10. PubMed ID: 21904204
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
Keam SJ; Cvetković RS
BioDrugs; 2009; 23(1):63-8. PubMed ID: 19344193
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
13. Telaprevir for retreatment of HCV infection.
Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: a single United Arab Emirates center experience.
Giguere A; Anas A; Nasser T; Hassan MH; Ahmed U; Beejay N; Nouh M; Khalowf M; Saleh A; Khan A; Attia M; El-Azab G
Eur J Intern Med; 2011 Dec; 22(6):582-6. PubMed ID: 22075284
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe.
Husa P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Urbanek P
Eur J Gastroenterol Hepatol; 2011 May; 23(5):375-81. PubMed ID: 21502923
[TBL] [Abstract][Full Text] [Related]
18. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
19. Preliminary study of two antiviral agents for hepatitis C genotype 1.
Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
[TBL] [Abstract][Full Text] [Related]
20. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
